Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seiya Ichihara

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Thoracic Cancer|December 15, 2022
Non-small cell lung cancer with EGFR (L858R and E709X) and CNNB1 mutations responded to afatinibMichihiro Kunishige, Seiya Ichihara, Naoki Kadota, et al.
Thoracic Cancer|November 22, 2022
Late-onset acute type 1 diabetes mellitus 7 months after discontinuation of pembrolizumab against lung cancerSeiya Ichihara, Michihiro Kunishige, Naoki Kadota, et al.
Respiratory Investigation|May 25, 2026
Early risk response to vasodilators and outcomes in interstitial lung disease associated pulmonary hypertensionRyo Teramachi, Jun Fukihara, Seiya Ichihara, et al.
Medicine|July 15, 2025
Successful pembrolizumab treatment in a patient with ALK-positive lung adenocarcinoma: A case report and literature reviewYugo Matsumura, Seiya Ichihara, Kaori Nii, et al.
Cancer Reports (Hoboken, N.J.)|July 7, 2025
First-Line Osimertinib for EGFR-Mutated Squamous Cell Lung Carcinoma: A Case ReportYugo Matsumura, Seiya Ichihara, Kaori Nii, et al.
Thoracic Cancer|September 5, 2023
Pretreatment eosinophil counts as a predictive biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitorsEiji Takeuchi, Kensuke Kondo, Yoshio Okano, et al.
Thoracic Cancer|December 17, 2024
Pathological Complete Response to a Single Dose of Pembrolizumab-Based Chemoimmunotherapy for Squamous Cell Carcinoma of the Lung: A Case ReportYugo Matsumura, Seiya Ichihara, Kaori Nii, et al.
Thoracic Cancer|December 13, 2023
An increased relative eosinophil count as a predictive dynamic biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitorsEiji Takeuchi, Hirokazu Ogino, Kensuke Kondo, et al.
Respiratory Medicine Case Reports|December 30, 2022
Immune checkpoint inhibitor-related pneumonitis with atypical radiologic features in a patient with anti-aminoacyl-tRNA synthetase antibodySeiya Ichihara, Hirokazu Ogino, Hiroto Yoneda, et al.
Microbiology Spectrum|February 10, 2026
Diagnostic utility of quantitative interferon-gamma release assays in elderly patients with tuberculosisYoshikazu Mutoh, Yusuke Minato, Yuya Kawamoto, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Thoracic Cancer|December 15, 2022
Non-small cell lung cancer with EGFR (L858R and E709X) and CNNB1 mutations responded to afatinibMichihiro Kunishige, Seiya Ichihara, Naoki Kadota, et al.
Thoracic Cancer|November 22, 2022
Late-onset acute type 1 diabetes mellitus 7 months after discontinuation of pembrolizumab against lung cancerSeiya Ichihara, Michihiro Kunishige, Naoki Kadota, et al.
Respiratory Investigation|May 25, 2026
Early risk response to vasodilators and outcomes in interstitial lung disease associated pulmonary hypertensionRyo Teramachi, Jun Fukihara, Seiya Ichihara, et al.
Medicine|July 15, 2025
Successful pembrolizumab treatment in a patient with ALK-positive lung adenocarcinoma: A case report and literature reviewYugo Matsumura, Seiya Ichihara, Kaori Nii, et al.
Cancer Reports (Hoboken, N.J.)|July 7, 2025
First-Line Osimertinib for EGFR-Mutated Squamous Cell Lung Carcinoma: A Case ReportYugo Matsumura, Seiya Ichihara, Kaori Nii, et al.
Thoracic Cancer|September 5, 2023
Pretreatment eosinophil counts as a predictive biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitorsEiji Takeuchi, Kensuke Kondo, Yoshio Okano, et al.
Thoracic Cancer|December 17, 2024
Pathological Complete Response to a Single Dose of Pembrolizumab-Based Chemoimmunotherapy for Squamous Cell Carcinoma of the Lung: A Case ReportYugo Matsumura, Seiya Ichihara, Kaori Nii, et al.
Thoracic Cancer|December 13, 2023
An increased relative eosinophil count as a predictive dynamic biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitorsEiji Takeuchi, Hirokazu Ogino, Kensuke Kondo, et al.
Respiratory Medicine Case Reports|December 30, 2022
Immune checkpoint inhibitor-related pneumonitis with atypical radiologic features in a patient with anti-aminoacyl-tRNA synthetase antibodySeiya Ichihara, Hirokazu Ogino, Hiroto Yoneda, et al.
Microbiology Spectrum|February 10, 2026
Diagnostic utility of quantitative interferon-gamma release assays in elderly patients with tuberculosisYoshikazu Mutoh, Yusuke Minato, Yuya Kawamoto, et al.
Pageof 2